Company Overview of BioNJ Inc.
BioNJ Inc. operates a network of members representing research-based life sciences companies and other related contributors. It stimulates and supports the discovery, development, and commercialization of therapies and cures by companies engaged in biopharmaceutical, biomedical, bio-agricultural, and bio-remedial endeavors. The company also provides purchasing consortium programs; and talent services, such as mentor networks, talent acquisitions, training and education, transition programs, HR networking, jobs databases and links, and specialty services for human resources and staffing requirements. In addition, it offers programs on project management, leadership, Six Sigma, root cause anal...
1255 Whitehorse-Mercerville Road
Building B – Suite 514
Trenton, NJ 08691
Founded in 1994
Key Executives for BioNJ Inc.
Chief Executive Officer, President and Trustee
Vice President of Operations
Vice President of Communications and Marketing
Compensation as of Fiscal Year 2015.
BioNJ Inc. Key Developments
Biotechnology Industry Organization Appoints James Sapirstein BIO's ECS Board of Directors and BioNJ's Board of Trustees
Jun 15 15
ContraVir Pharmaceuticals Inc. announced the appointment of ContraVir CEO James Sapirstein to the Biotechnology Industry Organization Emerging Companies Section Governing Board (ECSGB) and the Capital Formation Committee. Additionally, Mr. Sapirstein has been appointed to the Board of Trustees of BioNJ. James Sapirstein brings more than 30 years of experience in the pharmaceutical industry to BIO and BioNJ and continues to advocate support for the life sciences industry both within ContraVir's home state and across the country.
BioNJ Appoints Three New Board Members
May 5 15
BioNJ announced the recent appointment of three new Board Members. The new Board Members elected on April 29, 2015, are James Sapirstein, Ambaw Bellete and Paul G. Howes. James Sapirstein, R.Ph., MBA, Chief Executive Officer, ContraVir Pharmaceuticals Inc. Prior to joining ContraVir Pharmaceuticals, Mr. Sapirstein was CEO of Alliqua Therapeutics at Alliqua Inc. Mr. Bellete has nearly 25 years of experience in the biopharmaceutical and medical device industry. Mr. Bellete has held senior executive positions across multiple therapeutic areas in business development, commercial operations, managed care, marketing and sales at companies such as Pharmacia and Sanofi. Prior to joining Photocure, he was most recently President of Medical Compression Systems. Mr. Howes currently serves as Executive Chairman of ThromboGenics Inc. Additionally, he serves as a Director on the parent company’s Board. Prior to ThromboGenics, Mr. Howes was the President and CEO of Inotek Pharmaceuticals.
BioNJ Announces Board Changes
Mar 16 15
BioNJ announced the appointment of a new Chairman of the Board of Trustees and two new Board Members. Stuart Peltz, Ph.D., CEO of PTC Therapeutics, was elected Chairman of BioNJ, succeeding Francois Nader, M.D., former President and CEO of NPS Pharma (recently acquired by Shire PLC) who concluded a two-year term. Dr.
Peltz has been a Member of the Board since January 2005. Dr. Peltz is the co-founder of PTC Therapeutics, a company he spun out of Rutgers University Robert Wood
Johnson Medical School, and has served as CEO and a Member of the Board of Directors since the company's inception in 1998. Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. At the meeting, two new Members joined the BioNJ Board of Trustees: Mohamed H. Ragab, M.D., Vice President, Search & Evaluation, Oncology and Business Development at Bristol-Myers Squibb Company and Paul Chew, M.D., Senior Vice President, Group Chief Medical Officer and Head of the North American R&D Hub for Sanofi.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|